Gland Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE068V01023
  • NSEID: GLAND
  • BSEID: 543245
INR
3,331.35
40.3 (1.22%)
BSENSE

Nov 20

BSE+NSE Vol: 3.17 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Ajanta Pharma
Gland Pharma
Emcure Pharma
Ipca Labs
Anthem Bioscienc
Glaxosmi. Pharma
Glenmark Pharma
Alkem Lab
Abbott India
Lupin
Biocon
Why is Gland Pharma Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
The company has declared Positive results for the last 4 consecutive quarters
  • PAT(Latest six months) At Rs 607.72 cr has Grown at 52.25%
  • ROCE(HY) Highest at 16.31%
  • NET SALES(Q) Highest at Rs 1,833.59 cr
3
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 09-Nov-26
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST and OBV
4
Market Beating performance in long term as well as near term
  • Along with generating 83.36% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you buy?
  1. Overall Portfolio exposure to Gland Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Gland Pharma for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Gland Pharma
83.36%
2.27
36.76%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
12.18%
EBIT Growth (5y)
2.55%
EBIT to Interest (avg)
71.93
Debt to EBITDA (avg)
0.16
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.58
Tax Ratio
28.72%
Dividend Payout Ratio
42.46%
Pledged Shares
0
Institutional Holding
43.59%
ROCE (avg)
18.66%
ROE (avg)
10.04%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
44
Industry P/E
40
Price to Book Value
5.13
EV to EBIT
34.89
EV to EBITDA
26.85
EV to Capital Employed
6.88
EV to Sales
7.30
PEG Ratio
0.75
Dividend Yield
0.60%
ROCE (Latest)
19.73%
ROE (Latest)
11.73%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company
PAT(Latest six months)

At Rs 607.72 cr has Grown at 52.25%

ROCE(HY)

Highest at 16.31%

NET SALES(Q)

Highest at Rs 1,833.59 cr

-2What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Gland Pharma
Profit After Tax (PAT) - Latest six months
At Rs 607.72 cr has Grown at 52.25%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
Highest at Rs 1,833.59 cr and Grown
each quarter in the last five quarters
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)